Glykos Finland
Develops antibody-drug conjugates and glycan analysis services for pharmaceutical companies and research institutions
Highlights
- New on EvolcAdded 2026-10-28
About Glykos Finland
Glykos Finland develops antibody-drug conjugates (ADCs) for hematologic and solid tumors using its proprietary linker and cytotoxic payload technologies. Its pipeline includes GLK-33, an ADC candidate targeting CD33-expressing blood cancers.
The company collaborates with pharmaceutical partners and antibody developers through research and licensing agreements. It also provides glycan profiling, structural characterization and biomarker research services to pharmaceutical companies and research institutions.
Founded in 2004, Glykos Finland is headquartered in Helsinki. Its partners include Orion and Genovis.
Product: Antibody-drug conjugate technologies and oncology candidates, alongside glycan analysis and biomarker research services.
Jobs at Glykos Finland
More biotech & pharma companies
Grindeks Kalceks Suomi
Finnish subsidiary that imports and sells prescription, hospital, pharmacy and self-care medicines made at its parent's European plantsYoung companyNew on EvolcHumGel
Human tumor-derived cell matrix (MyoGel) for cancer research labs running invasion and drug-testing assaysYoung companyNew on EvolcKÄÄPÄ BioTech
Standardised functional mushroom extracts for pharmaceutical, nutraceutical and wellness product developersNew on EvolcLignoSphere Company
Colloidal lignin particles from kraft lignin for coating and adhesive manufacturers seeking fossil-free phenolic substitutesYoung companyNew on EvolcLinio Biotech
Regenerative tissue platform (Tience) for skin and soft-tissue defect treatment, used by clinicians in the NordicsNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Bootstrap
- Cloudflare
- Google Analytics 4
- Google Universal Analytics
- jQuery
- nginx